Status:

TERMINATED

A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease

Lead Sponsor:

Bristol-Myers Squibb

Conditions:

Alzheimer's Disease

Eligibility:

All Genders

45-90 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to determine the safety and tolerability of BMS-708163 in patients with Prodromal Alzheimer's disease over a treatment period of a minimum of 104-weeks. In addition patien...

Eligibility Criteria

Inclusion

  • Patient meets clinical criteria for prodromal Alzheimer's disease (MMSE 24-30)
  • Memory complaint by subject or study partner
  • CSF aβ42 levels \< 200pg/mL or Total Tau/aβ42 ratio of ≥ 0.39
  • Score of ≤4 on the Modified Hachinski Ischemia Scale
  • CT results consistent with Alzheimer's disease
  • Medically stable
  • 6 years education
  • Reliable study partner
  • Must be able to swallow capsules

Exclusion

  • Premenopausal women
  • DSM-IV diagnosis of Dementia History of stroke
  • Immunocompromised
  • Active peptic ulcer, GI bleed, chronic inflammatory bowel disease, chronic diarrhea or past GI surgery that would impact drug absorption
  • Unstable Vitamin B-12 deficiency
  • Hematologic or solid malignancy within 5 years
  • Geriatric Depression Scale ≥ 6
  • Unstable medical condition
  • Alcohol or drug abuse history with 12-months of study entry
  • Significant drug allergy
  • Prisoners, compulsory psychiatric patients, or residents of nursing home or skilled nursing facility at entry
  • Any other experimental therapy with 30-days of study entry

Key Trial Info

Start Date :

May 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2013

Estimated Enrollment :

263 Patients enrolled

Trial Details

Trial ID

NCT00890890

Start Date

May 1 2009

End Date

July 1 2013

Last Update

October 12 2015

Active Locations (64)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 16 (64 locations)

1

University Of Alabama At Birmingham

Birmingham, Alabama, United States, 35294

2

Pivotal Research Centers

Peoria, Arizona, United States, 85381

3

21st Century Neurology

Phoenix, Arizona, United States, 85004

4

Banner Alzheimer'S Institute

Phoenix, Arizona, United States, 85006

A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease | DecenTrialz